Molecular Partners Advanced Phase 2 Study Of MP0317 In Cholangiocarcinoma; Stock Up

Source and reference

source on Google Add Now Molecular Partners AG ( MOLN ) has announced clinical progress in its Phase 2 proof-of-concept study evaluating MP0317 in combination with chemoimmunotherapy for patients with advanced biliary tract carcinoma (TACTIC), also known as cholangiocarcinoma. Cholangiocarcinoma is a rare and aggressive cancer of the bile ducts, often diagnosed at advanced stages. Current treatment options are limited, and prognosis remains poor, underscoring the need for new therapeutic approaches. The randomized, multicenter study in France is designed to enroll 75 patients, with 50 receiving MP0317 alongside standard-of-care (SoC) durvalumab plus gemcitabine-cisplatin-chemotherapy, and 25 receiving SoC alone. Nine trial sites are currently active, and patient treatment is ongoing. A data update is expected in 2027, with study completion targeted for 2028. A trial-in-progress...